Role of Radiotherapy and Hormone Therapy in Patients with Node-Positive Locally Advanced Prostate Cancer
Arch. esp. urol. (Ed. impr.)
; 76(10): 718-732, diciembre 2023. tab, ilus
Article
in En
| IBECS
| ID: ibc-229532
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
New-generation imaging techniques and the increasing use of surgery in high-risk prostate cancer (PCa) allow usto detect many cases of nodal disease at initial diagnosis or after resection. The treatment of PCa with pathologic regional nodeshas evolved from the exclusive use of systemic therapy to its combination with locoregional treatment. It can also represent abenefit in the overall survival. However, the evidence from randomised studies is limited. Thus, we review the most relevantresults in this scenario.Materials and Methods: A literature search was conducted in MEDLINE, PubMed, EMBASE, Clinical-Trials.gov and Webof Science on January 2023 to review node-positive PCa by considering the relevant literature on this topic published with norestrictions on date and language. The search keywords used were Prostatic Neoplasms (MeSh) and Node-positive (TextWord) and Radiotherapy (MeSh) and (Androgen Antagonists (MeSh) or Antineoplastic Agents, Hormonal (MeSh)), whichare indexed within the Medical Subject Headings database.Results: The management of node-positive PCa has no clear definitive consensus at the initial disease diagnosis or after surgery.However, in this review, we summarise the existing literature for the management of these patients in both scenarios, consideringimaging tests, radiotherapy, hormone therapy and second-generation hormonal treatments.Conclusions: The combination of radiotherapy and androgen-deprivation therapy is the treatment of choice. The addition ofsecond-generation hormone therapy, plus the intensification of radiotherapy schedules, will likely change the treatment paradigm for these patients. (AU)
Key words
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Prostatic Neoplasms
/
Consensus
/
Androgen Antagonists
/
Androgens
Limits:
Humans
Language:
En
Journal:
Arch. esp. urol. (Ed. impr.)
Year:
2023
Document type:
Article